Has Juan Andino, MD received payments from drug or device companies?

Yes. Drug and device makers reported $59,175 in general payments to Juan Andino, MD across 123 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Juan Andino, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Juan Andino, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Juan Andino, MD

Urology · Los Angeles, CANPI 1053846584

Payments from drug & device makers

What this record shows

This record is dominated by grants: $50,000 of the $59,175 with a category attached, or 84.5%. Boston Scientific accounts for 90.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $51,842 and has fallen 94.9% since, to $2,619 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,175in general payments, 2019–2025

Across 123 payments — averaging $481.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$54K
Coloplast$3K
Endo Pharmaceuticals Inc.$627
Antares Pharma, Inc.$491
Endo USA, Inc.$318
Urogen Pharma, Inc.$174
plus $1K from 14 others

What the payments were for

Consulting fees$4501%
Grants$50,00084%
Travel & lodging$9242%
Food & beverage$7,80113%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	52	$53,645
Coloplast	25	$2,909
Endo Pharmaceuticals Inc.	8	$627
Antares Pharma, Inc.	6	$491
Endo USA, Inc.	6	$318
Urogen Pharma, Inc.	2	$174
Teleflex LLC	3	$143
Innovation Technologies Inc	2	$141
Procept Biorobotics Corporation	1	$133
Angiodynamics, Inc.	2	$118
Integra Lifesciences Corporation	3	$93
AbbVie	2	$63
Dentsply IH AB	2	$61
Baxter Healthcare	1	$56
Halozyme Inc	2	$49
Cook Medical LLC	2	$41
EMD Serono, Inc.	1	$37
Biotissue Holdings Inc.	1	$29
Sumitomo Pharma America, Inc.	1	$24
Johnson & Johnson	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GENERAL ERECTILE DYSFUNCTION$50,000
TITAN$2,494
XIAFLEX$627
AdVance XP$553
TACTRA$553
AMS 700$516
XYOSTED$390
GENERAL - THERAPIES$245
JELMYTO$158
AquaBeam Robotic System$133
Irrisept$133
NOCDURNA$123
TLANDO$123
Advantage System$111
AMS 800 Artificial Urinary Sphincter$107

How this compares

$59,175 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024

$43,124

Medicare patients

152

Services billed

4,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	14	$13,623
Testosterone	25	$2,539
Testosterone Cypionate	37	$1,256
Trospium Chloride	13	$791
Tamsulosin Hcl	29	$402
Finasteride	19	$326
Alfuzosin Hcl ErAlfuzosin Hcl	13	$146
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	12	$21

Paid to pharmacies, not to this prescriber.

Other urology in Los Angeles

Arie BelldegrunLos Angeles$1.8M
Mihir DesaiLos Angeles$1.5M
Stuart HoldenLos Angeles$1.1M
William AronsonLos Angeles$540K
Amir LebastchiLos Angeles$478K
Nazy ZomorodianLos Angeles$309K
Jeffrey Loh-DoyleLos Angeles$308K
Siamak DaneshmandLos Angeles$306K
Karim ChamieLos Angeles$291K
Brian ShuchLos Angeles$166K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →